Table 2.

Wording of clinical guidelines on the value of PSMA-ligand PET/CT for primary, biochemical persistence (BCP), biochemical recurrence (BCR), and metastatic prostate cancer assessments

Document led by	Initial staging	Localization of BCP	Localization of BCR	Metastatic*	Reference
EAU	“more accurate”	“offer”	“perform”	N/A*	[45, 47, 48]
ESMO	“better sensitivity and specificity than CT or bone scan”	N/A	“replacing conventional imaging”	N/A*	[81]
ASCO	“consider”	“should be offered”	“should be offered”	N/A*	[82]
NCCN	“equally effective, if not more effective” compared to conventional imaging”	“equally effective, if not more effective” compared to conventional imaging”	“equally effective, if not more effective” compared to conventional imaging”	N/A*	[83]

N/A, not evaluated. *PSMA-ligand PET/CT is required before PSMA-directed RLT